Ablynx Proposes to Strengthen Its Board With the Appointment of Dr Roger Perlmutter and Dr Russell Greig

GHENT, BELGIUM--(Marketwire - September 27, 2012) - Ablynx (EURONEXT BRUSSELS: ABLX) today announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company’s forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.

Dr Edwin Moses, Chairman and CEO of Ablynx, said:

“We are delighted that Roger and Russell are prepared to join the Ablynx Board. We expect to benefit enormously from their extensive experience in major pharmaceutical companies as well as their numerous interactions with biotechnology companies at all stages of development. We see these appointments as a very important step in the recognition of Ablynx’s unique Nanobody platform and in the continuing evolution of Ablynx into a significant player in the international biopharmaceutical industry.”

Dr Roger Perlmutter

Dr Perlmutter was Executive Vice President, Research and Development, at Amgen Inc, the world’s largest biotechnology company, from 2001 to 2012. Before joining Amgen, he was the Executive Vice President of Worldwide Basic Research and Preclinical Development at Merck and Co. Prior to joining Merck, Dr Perlmutter had been Professor and founding Chairman of the Department of Immunology at the University of Washington, Seattle, USA.

Dr Perlmutter is currently a Director of StemCells Inc. and the Immune Design Corporation. He is also Chairman of the Board of Trustees of Reed College and a Director of the Institute for Systems Biology (a not-for-profit research institute based in Seattle, Washington). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science and a past President of the American Association of Immunologists. Ablynx is the first potential Board mandate that Dr Perlmutter has accepted outside the USA.

Dr Russell Greig

Dr Greig has more than 30 years’ experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr Greig was also President of SR One, GSK’s Corporate Venture Group. He is currently Chairman of Syntaxin (UK), AM Pharma (The Netherlands) and Isconova (Sweden) as well as a Director of Tigenix (Belgium). He also acts as a consultant to Genocea (US), BigDNA (Scotland), Edinburgh BioQuarter (Scotland), and Kurma Life Sciences (France). He served as acting CEO at Genocea and Isconova for an interim period. He is also a member of the Scottish Scientific Advisory Committee.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(®), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

press release in pdf: http://hugin.info/137912/R/1643851/529505.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

[HUG#1643851]